Dr. Xiaolin Zi received a new DoD idea development award (PC230464). The proposal entitled "An Epigenetic Approach for Alleviating Enzalutamide Resistance in Prostate Cancer" is recommended for funding by Congressionally Directed Medical Research Programs (CDMRP) through August 2027 with a total budget of $1.4 million. The overall goal of this project is to develop novel agents for targeting dysregulated epigenetic factors to overcoming Enzalutamide (also called XTANDI®) unresponsiveness and enhancing its efficacies for treatment of advanced prostate cancer.